Show simple item record

dc.contributor.authorFazekas, Barbara
dc.contributor.authorGriffin, Matthew D.
dc.date.accessioned2021-01-04T14:51:24Z
dc.date.issued2020-01-28
dc.identifier.citationFazekas, Barbara, & Griffin, Matthew D. (2020). Mesenchymal stromal cell–based therapies for acute kidney injury: progress in the last decade. Kidney International, 97(6), 1130-1140. doi:https://doi.org/10.1016/j.kint.2019.12.019en_IE
dc.identifier.issn0085-2538
dc.identifier.urihttp://hdl.handle.net/10379/16399
dc.description.abstractA little over 10 years ago, the therapeutic potential of mesenchymal stromal cells (MSCs) for the treatment of acute kidney injury (AKI) was becoming widely recognized. Since then, there has been further intensive study of this topic with a clear translational intent. Over the past decade, many more animal model studies have strengthened the evidence that systemically or locally delivered MSCs ameliorate renal injury in sterile and sepsis-associated AKI. Some of these preclinical studies have also provided a range of compelling new insights into the in vivo fate and mechanisms of action of MSCs in the setting of AKI and other inflammatory conditions. Coupled with increased knowledge of the functional roles of resident and infiltrating immune cell mediators in determining the severity and outcome of AKI, the progress made in the past decade would appear to have significantly strengthened the translational pathway for MSC-based therapies. In contrast, however, the extent of the clinical experience with MSC administration in human subjects with AKI or sepsis-associated AKI has been limited to a small number of early-phase clinical trials, which appear to demonstrate safety but have not thus far delivered a strong signal of efficacy. In this review, we summarize the most significant new developments in the field of MSC-based therapies as they relate to AKI and reflect on the key gaps in knowledge and technology that remain to be addressed for the true clinical potential of MSCs and, perhaps, other emerging cellular therapies to be realized.en_IE
dc.description.sponsorshipBF was supported by an Irish Research Council Enterprise Partnership Postdoctoral Fellowship (grant number EPSPD/2017/106). MDG is supported by grants from the European Commission [Horizon 2020 Collaborative Health Project NEPHSTROM (grant number 634086) and FP7 Collaborative Health Project VISICORT (grant number 602470)], from Science Foundation Ireland [REMEDI Strategic Research Cluster (grant number 09/SRC-B1794; MDG) and CÚRAM Research Centre (grant number 13/RC/2073; MDG)] and the European Regional Development Fund.
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherElsevieren_IE
dc.relation.ispartofKidney Internationalen
dc.subjectCISPLATIN-INDUCED NEPHROTOXICITYen_IE
dc.subjectINDUCED RENAL INJURYen_IE
dc.subjectREGULATORY T-CELLSen_IE
dc.subjectSTEM-CELLSen_IE
dc.subjectSEPTIC SHOCKen_IE
dc.subjectTUBULOINTERSTITIAL FIBROSISen_IE
dc.subjectHEME OXYGENASE-1en_IE
dc.subjectPROGENITOR CELLSen_IE
dc.subjectSEPSISen_IE
dc.subjectPROTECTen_IE
dc.titleMesenchymal stromal cell–based therapies for acute kidney injury: progress in the last decadeen_IE
dc.typeArticleen_IE
dc.date.updated2020-12-19T17:33:38Z
dc.identifier.doi10.1016/j.kint.2019.12.019
dc.local.publishedsourcehttps://doi.org/10.1016/j.kint.2019.12.019en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderIrish Research Council
dc.contributor.funderHorizon 2020
dc.contributor.funderEuropean Regional Development Fund
dc.contributor.funderScience Foundation Ireland
dc.description.embargo2021-01-28
dc.internal.rssid21697342
dc.local.contactMatthew Dallas Griffin, Remedi, Biomedical Sciences Buil, Corrib Village, Dangan, Nui Galway. 5436 Email: matthew.griffin@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/EC/H2020::RIA/634086/EU/Novel Stromal Cell Therapy for Diabetic Kidney Disease/NEPHSTROM
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/602470/EU/Adverse Immune Signatures and their Prevention in Corneal Transplantation/VISICORT
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Strategic Research Cluster/09/SRC/B1794/IE/SRC REMEDI: REMEDI-2: From Research to Human Therapy/
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/13/RC/2073/IE/C�RAM - Centre for Research in Medical Devices/
nui.item.downloads1


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record